While inherent resistance to Nutlin-3a exists in TP53 mutant carcinomas, acquired resistance to Nutlin-3 may occur via acquisition of de novo TP53 mutations [43] or overexpression of MDM4 [44]. This evidence concerns the gene MDM4 and carcinoma.